
Medtech Aspivix secures EUR 1.95 million in crowdfunding
20 January 2025

Start-up Aspivix has raised EUR 1.95 million through a crowdfunding campaign to advance the commercialization of its innovative gynecological device, Carevix™. The campaign, hosted on the Capital Cell platform, aims to reach a target of EUR 2.15 million by 15 March 2025.
Aspivix, which is headquartered in the canton of Vaud, is revolutionizing gynecological practices with Carevix™, a device designed to replace traditional Pozzi forceps. The device uses gentle suction to stabilize the cervix, significantly reducing pain, bleeding, and stress associated with gynecological procedures. Carevix™ is FDA-cleared for the U.S. market, CE-marked for the EU, and approved in the UK and Brazil. Already in use across a network of clinics in the U.S., the device is poised for broader adoption.
The journey began with a conversation between brothers—Julien Finci, an engineer, and David Finci, a gynecologist—who identified the discomfort caused by Pozzi forceps as a critical area for improvement. With the expertise of co-founder Mathieu Horras, Carevix™ was developed as a patient-friendly alternative. Protected by several patents, the device is a game-changer for gynecological care, combining simplicity with cutting-edge technology.
Powered by Swiss Innovation
Aspivix’s growth is supported by the vibrant Western Switzerland “Health Valley” ecosystem. Partnerships with the University Hospital of Lausanne (CHUV), EPFL, and HEIG-VD have played a crucial role in product development and clinical validation. Backed by initiatives such as Innosuisse and Innovaud, the company has attracted strategic collaborations, including a partnership with Bayer in 2024.
The company’s achievements have garnered international recognition, with Time magazine naming Carevix™ among the 200 best inventions of 2024. The crowdfunding campaign will enable Aspivix to scale production and expand its presence in key markets. Aspivix’s crowdfunding initiative has attracted 85 investors to date, demonstrating broad support for its mission to improve women’s healthcare. As the campaign progresses, Aspivix remains committed to leveraging its innovative technology to bring comfort and dignity to patients worldwide.